The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search feed instagram google-plus avvo phone envelope checkmark mail-reply spinner error close The Legal Examiner The Legal Examiner The Legal Examiner
Skip to main content
| Dr. Shezad Malik Law Firm

Invokana Diabetic Ketoacidosis Injury. Ronney Lyons, from Houston, Texas recently filed an Invokana product liability and personal injury lawsuit against Janssen Pharmaceuticals and it’s parent company, Johnson & Johnson. According to Lyons in his Invokana injury lawsuit, the serious side effects of Invokana caused him to develop diabetic ketoacidosis injury.

Invokana Amputation Injuries
Invokana Diabetic Ketoacidosis Side Effects. According to many lawsuits, Invokana is linked to kidney failure, heart attacks, leg amputations and a build up of acid in the body known as diabetic ketoacidosis

Invokana Diabetic Ketoacidosis Injury

Invokana Diabetic Ketoacidosis Injury. Invokana linked to kidney failure, leg amputations, and diabetic ketoacidosis according to lawsuits.

What is Invokana?

Invokana (canagliflozin) is a new type 2 diabetic medication released in March 2013 and has been touted by Janssen Pharmaceuticals and Johnson & Johnson as being superior to the older types of diabetic medications.

Invokana increases the amount of sugar excreted in the urine. Invokana has been plagued by the FDA, who has required several Invokana warning updates.

Lyons in his Invokana injury lawsuit claims that the drug makers failed to adequately research the medication or warn patients and doctors about the potential health risks with Invokana.

FDA Invokana Diabetic Ketoacidosis Injury and Warnings

In December 2015, the FDA required Johnson & Johnson to add new diabetic ketoacidosis warnings to Invokana, highlighting that the medication significantly increases the risk of this potentially deadly condition. Patients were advised by the FDA to stop taking Invokana and seek medical attention immediately if they have any symptoms of ketoacidosis, a serious condition in which the body produces high levels of blood acids called ketones. The FDA warning included data about severe urinary tract infections from Invokana use.

A recent study in the New England Journal of Medicine confirmed the findings.

In June 2016, the FDA required additional label warnings about the link between Invokana and kidney risks, highlighting that the medication may increase the risk of acute kidney injury.

Invokana doubles Amputation risk according to studies

Based on new data from two large clinical trials, the FDA in May 2017 concluded that the type 2 diabetes medicines Invokana, Invokamet, Invokamet XR caused an increased risk of leg and foot amputations.

The FDA is requiring new warnings, including their most prominent Boxed Warning, to be added to the Invokana drug labels to describe this risk.

Final results from two clinical trials – the CANVAS (Canagliflozin Cardiovascular Assessment Study) and CANVAS-R (A Study of the Effects of Canagliflozin on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus) – showed that leg and foot amputations occurred about twice as often in patients treated with Invokana compared to patients treated with placebo, which is an inactive treatment.

Invokana Federal Multidistrict Litigation

Since December 2016, all federally-filed Invokana injury lawsuits have been consolidated as part of the federal Invokana multidistrict litigation (MDL), which is centralized before U.S. District Judge Brian Martinotti in the District of New Jersey to coordinate discovery and pretrial proceedings.

If you or someone you know succumbed to an Invokana Ketoacidosis, leg amputations or kidney failure from taking Invokana for the treatment of their type 2 diabetes, please call us for further information at 888-210-9693. Dr. Shezad Malik Law Firm is investigating Invokana Ketoacidosis, leg amputations or kidney failure from taking Invokana for the treatment of their type 2 diabetes.

Comments for this article are closed, but you may still contact the author privately.